---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-037898"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2024-12-19T23:59:59+00:00"
generated_at: "2026-05-29T01:11:54.801286+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Omeros narsoplimab meets TA-TMA pivotal trial primary endpoint; HR 0.32 for survival

## Summary
- Narsoplimab-treated TA-TMA patients had over 3-fold reduction in risk of death (HR 0.32, 95% CI 0.23-0.44, p<0.00001) vs >100 external control patients.
- Omeros will resubmit the narsoplimab BLA to FDA as soon as possible for first approved TA-TMA therapy.
- Expanded access program data: 46% of adults and 50% of children achieved TA-TMA resolution after failing C5 inhibitors.
- European marketing authorisation application planned for Q2 2025; additional sensitivity analyses and manuscripts expected early 2025.

## SEC filing metadata
- accession: 0001437749-24-037898
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2024-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000143774924037898/0001437749-24-037898-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000143774924037898/omer20241210_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-037898
- JSON: https://secwatch.observer/filing/0001437749-24-037898.json
- Plain text: https://secwatch.observer/filing/0001437749-24-037898.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.